Last updated: August 30, 2023
Sponsor: Central Hospital, Nancy, France
Overall Status: Active - Recruiting
Phase
N/A
Condition
Chest Pain
Cardiac Surgery
Heart Failure
Treatment
No Levosimendan
Levosimendan
Clinical Study ID
NCT06021587
2023_PI_084
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with heart failure impaired LVEF (< 40%), who have undergone left heartsurgery (coronary artery bypass grafting and/or mitral and/or aortic valvereplacement) under extracorporeal circulation between 01/01/2018 and 28/02/2022 atdifferent University Hospital in France
Exclusion
Exclusion Criteria:
- Initiation of levosimendan > 48 hours or < 24 hours before surgery ECMO pre- orpost-op
Study Design
Total Participants: 300
Treatment Group(s): 2
Primary Treatment: No Levosimendan
Phase:
Study Start date:
July 01, 2023
Estimated Completion Date:
October 10, 2023
Connect with a study center
'CHRU Nancy
Vandœuvre-lès-Nancy, Meurthe Et Moselle 54530
FranceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.